S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54

Catalent Stock Forecast, Price & News

-3.73 (-3.36%)
(As of 06/28/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
758,761 shs
Average Volume
1.24 million shs
Market Capitalization
$19.20 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Stock Forecast (MarketRank)

Overall MarketRank

2.29 out of 5 stars

Medical Sector

290th out of 1,433 stocks

Pharmaceutical Preparations Industry

120th out of 685 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
Catalent logo

About Catalent (NYSE:CTLT)

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

CTLT Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
$529 million
Pretax Margin


Sales & Book Value

Annual Sales
$4.00 billion
Cash Flow
$4.64 per share
Book Value
$22.98 per share


Free Float
Market Cap
$19.20 billion

Catalent Frequently Asked Questions

Should I buy or sell Catalent stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Catalent stock.
View analyst ratings for Catalent
or view top-rated stocks.

What is Catalent's stock price forecast for 2022?

7 Wall Street research analysts have issued 12 month price objectives for Catalent's shares. Their CTLT stock forecasts range from $110.00 to $160.00. On average, they anticipate Catalent's stock price to reach $142.86 in the next year. This suggests a possible upside of 33.3% from the stock's current price.
View analysts' price targets for Catalent
or view top-rated stocks among Wall Street analysts.

How has Catalent's stock price performed in 2022?

Catalent's stock was trading at $128.03 at the start of the year. Since then, CTLT stock has decreased by 16.3% and is now trading at $107.14.
View the best growth stocks for 2022 here

Are investors shorting Catalent?

Catalent saw a increase in short interest in June. As of June 15th, there was short interest totaling 4,720,000 shares, an increase of 25.9% from the May 31st total of 3,750,000 shares. Based on an average daily trading volume, of 1,230,000 shares, the short-interest ratio is presently 3.8 days. Approximately 2.8% of the shares of the stock are sold short.
View Catalent's Short Interest

When is Catalent's next earnings date?

Catalent is scheduled to release its next quarterly earnings announcement on Monday, August 29th 2022.
View our earnings forecast for Catalent

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) announced its quarterly earnings results on Tuesday, May, 3rd. The company reported $1.00 earnings per share for the quarter, topping analysts' consensus estimates of $0.89 by $0.11. The business had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.22 billion. Catalent had a trailing twelve-month return on equity of 15.07% and a net margin of 10.72%. The company's revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.78 earnings per share.
View Catalent's earnings history

What guidance has Catalent issued on next quarter's earnings?

Catalent updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $3.67-$3.85 for the period, compared to the consensus estimate of $3.69. The company issued revenue guidance of $4.80 billion-$4.90 billion, compared to the consensus revenue estimate of $4.80 billion.

Who are Catalent's key executives?

Catalent's management team includes the following people:

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent CEO John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among Catalent's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.59%), BlackRock Inc. (8.72%), Capital World Investors (4.87%), State Street Corp (3.98%), Veritas Asset Management LLP (3.91%) and JPMorgan Chase & Co. (2.50%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Barry Littlejohns, Gregory T Lucier, Gregory T Lucier, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Mario Gargiulo, Michael J Grippo, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Thomas P Castellano and Wetteny Joseph.
View institutional ownership trends for Catalent

Which major investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Third Point LLC, Inverness Counsel LLC NY, Jennison Associates LLC, First Trust Advisors LP, Loomis Sayles & Co. L P, Brown Advisory Inc., and TimesSquare Capital Management LLC. Company insiders that have sold Catalent company stock in the last two years include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Mario Gargiulo, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Thomas P Castellano, and Wetteny Joseph.
View insider buying and selling activity for Catalent
or view top insider-selling stocks.

Which major investors are buying Catalent stock?

CTLT stock was bought by a variety of institutional investors in the last quarter, including Novo Holdings A S, Veritas Asset Management LLP, Viking Global Investors LP, JPMorgan Chase & Co., BlackRock Inc., Vanguard Group Inc., Eminence Capital LP, and State Street Corp.
View insider buying and selling activity for Catalent
or or view top insider-buying stocks.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $107.14.

How much money does Catalent make?

Catalent (NYSE:CTLT) has a market capitalization of $19.20 billion and generates $4.00 billion in revenue each year. The company earns $529 million in net income (profit) each year or $2.759990 on an earnings per share basis.

How many employees does Catalent have?

Catalent employs 17,300 workers across the globe.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for Catalent is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at [email protected], or via fax at 732-537-6480.

This page (NYSE:CTLT) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.